Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: September 19, 2008
Last updated: March 22, 2016
Last verified: March 2016
The purpose of this multicenter, single-arm, exact binomial single-stage, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors

Condition Intervention Phase
Gastrointestinal Stromal Tumors
Drug: Nilotinib
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • objective tumor response rate based on RECIST criteria (complete response (CR) and partial response PR) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • time to overall response (PR or CR) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • duration of response [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • progression free survival (PFS) during the first 6 months using RECIST criteria [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • overall survival (OS) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • safety and tolerability [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • population pharmacokinetics of Nilotinib [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 44
Study Start Date: August 2008
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: nilotinib Drug: Nilotinib
800 mg/d orally


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥18 years
  • Histologically confirmed diagnosis of GIST that is unresectable and/or metastatic and therefore not amenable to surgery or combined modality with curative intent prior to or at Visit 1
  • At least one measurable site of disease on CT/MRI scan at Visit 1, as defined by RECIST criteria (see Post Text Suppl 3 for details) The scans should be at maximum 2 weeks old. New scans are only required as baseline scans if they are older then approx. 2 weeks.
  • WHO Performance Status of 0, 1 or 2
  • Patients must have the following laboratory values (≥ LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication.):

    1. Potassium ≥ LLN,
    2. Magnesium ≥ LLN,
    3. Phosphorus ≥ LLN,
    4. Total calcium (corrected for serum albumin) ≥ LLN
  • Patients must have normal organ, electrolyte, and marrow function as defined below:

    1. Absolute Neutrophil Count (ANC) ≥ 1.5x 109/L;
    2. Platelets ≥ 100 x 109/L;
    3. ALT and AST ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if considered due to tumor;
    4. Alkaline phosphatase ≤ 2.5 x ULN unless considered due to tumor;
    5. Serum bilirubin ≤ 1.5 x ULN;
    6. Serum lipase and amylase ≤ 1.5 x ULN;
    7. Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min. (calculated creatinine clearance using Cockroft formula is acceptable)
  • Ability to understand and willingness to sign a written informed consent

Exclusion Criteria:

  • Prior treatment with nilotinib
  • Treatment with any cytotoxic and/or investigational cytotoxic drug ≤ 4 weeks (6 weeks for nitrosurea or mitomycin C) prior to Visit 1 with the exception of imatinib targeted therapy as an adjuvant therapy
  • Prior or concomitant malignancies requiring active treatment other than GIST with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ
  • Impaired cardiac function at including any one of the following:

    1. LVEF < 45% or below the institutional LLN range (whichever is higher) as determined by echocardiogram at Visit 1
    2. Complete left bundle branch block
    3. Use of a ventricular paced cardiac pacemaker
    4. Congenital long QT syndrome or family history of long QT syndrome
    5. History of or presence of significant ventricular or atrial tachyarrhythmias
    6. Clinically significant resting bradycardia (< 50 beats per minute)
    7. QTc > 450 msec on screening ECG (using the QTcF formula). If QTc > 450 msec and electrolytes are not within normal ranges (electrolytes should be corrected and then the patient rescreened for QTc.
    8. Right bundle branch block plus left anterior hemiblock, bifascicular block
    9. Myocardial infarction within 12 months prior to Visit 1
    10. Other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension,)
  • Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs, uncontrolled diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00756509

Novartis Investigative Site
HUS, Finland, FIN-00029
Novartis Investigative Site
Lyon Cedex, France, 69373
Novartis Investigative Site
Bad Saarow, Germany, 15526
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Muenchen, Germany, 81377
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Hospitalet de LLobregat, Cataluña, Spain, 08907
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46009
Novartis Investigative Site
Palma De Mallorca, Islas Baleares, Spain, 07120
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT00756509     History of Changes
Other Study ID Numbers: CAMN107DDE06  2008-000358-11 
Study First Received: September 19, 2008
Last Updated: March 22, 2016
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health

Keywords provided by Novartis:
unresectable or metastatic GIST
1st. line treatment

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue processed this record on May 26, 2016